During the past decade, Istituto Dermopatico dell'Immacolata - IDI - IRCCS conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Amryt Research Limited" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials sponsored and "Fondazione Melanoma Onlus" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" #1 collaborator was "Clinical Research Technology S.r.l." with 1 trials as a collaborator and "NCIC Clinical Trials Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" are "Melanoma" (2 trials), "Metastatic Melanoma" (2 trials), "Atrial Fibrillation" (1 trials), "Basal Cell Carcinoma" (1 trials) and "Epidermolysis Bullosa" (1 trials). Many other conditions were trialed in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" in a lesser frequency.

Most popular intervention types in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" are "Drug" (11 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Vemurafenib" (3 trials), "Atezolizumab" (1 trials), "Cobimetinib" (1 trials), "Control gel" (1 trials) and "Edoxaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS" are 13 trials for "All" genders.

Currently, there are NaN active trials in "Istituto Dermopatico dell'Immacolata - IDI - IRCCS". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Istituto Dermopatico dell'Immacolata - IDI - IRCCS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Dermopatico dell'Immacolata - IDI - IRCCS, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".